Drug Patents owned by Onyx Therap
1. List of Kyprolis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7232818 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US8207297 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US8207125 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US7417042 | ONYX THERAP | Compounds for enzyme inhibition |
Jul, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207127 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US8129346 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US7491704 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US8207126 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(2 years from now) | |
| US7737112 | ONYX THERAP | Composition for enzyme inhibition |
Dec, 2027
(4 years from now) | |
| USRE47954 | ONYX THERAP | Combination therapy with peptide epoxyketones |
Oct, 2029
(6 years from now) | |
| US9511109 | ONYX THERAP | Combination therapy with peptide epoxyketones |
Oct, 2029
(6 years from now) | |
| US9493582 | ONYX THERAP | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
Market Authorisation Date: 20 July, 2012
Treatment: Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic